Alison Stopeck
Overview
Explore the profile of Alison Stopeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raiss M, Mehta K, Zhang X, Kabacinski A, Martorana D, Mischo J, et al.
Support Care Cancer
. 2025 Feb;
33(3):206.
PMID: 39971803
Purpose: Unplanned readmissions have profound medical and financial implications for patients and hospitals. Cancer patients are particularly susceptible to readmission and often face complex care needs. This quality improvement project...
2.
Mastrogiacomo C, Courtepatte A, Moyer A, Preece C, Thompson P, Stopeck A
JCO Oncol Pract
. 2024 Oct;
:OP2400487.
PMID: 39481066
Purpose: The factors affecting women's willingness to participate (WTP) in breast cancer (BC) prevention trials are poorly understood. This study aimed to identify the characteristics of interventions associated with a...
3.
Zabrocka E, Polce S, Roberson J, Wu J, Cohen J, Baer L, et al.
Int J Radiat Oncol Biol Phys
. 2023 Oct;
118(2):436-442.
PMID: 37793576
Purpose: Surgery is the backbone of breast cancer (BC) treatment. For patients who cannot undergo surgery, improving local control (LC) of the primary tumor is paramount. To that end, this...
4.
Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner A, Stopeck A, et al.
Clin Cancer Res
. 2023 Jun;
29(24):5021-5030.
PMID: 37363965
Purpose: To overcome resistance to antihormonal and HER2-targeted agents mediated by cyclin D1-CDK4/6 complex, we proposed an oral combination of the HER2 inhibitor tucatinib, aromatase inhibitor letrozole, and CDK4/6 inhibitor...
5.
Mehta K, Nouvini R, Liu J, Wang Y, Stopeck A
Front Oncol
. 2023 Jan;
12:1061679.
PMID: 36686740
Breast cancer with choriocarcinomatous features (BCCF) is a rare and aggressive breast cancer. BCCF carries a poor prognosis and there is unfortunately scant literature to guide treatment beyond surgical resection...
6.
Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski R, Saad F, et al.
J Bone Oncol
. 2022 Mar;
33:100416.
PMID: 35242510
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE...
7.
Symonds L, Jenkins I, Linden H, Kurland B, Gralow J, Gadi V, et al.
Clin Breast Cancer
. 2021 Jun;
22(1):32-42.
PMID: 34158245
Introduction: Neoadjuvant chemotherapy is standard treatment for locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). We hypothesized that adding sunitinib, a tyrosine kinase inhibitor with antitumor and antiangiogenic...
8.
Streff A, Chu-Pilli M, Stopeck A, Chalasani P
Support Care Cancer
. 2020 Apr;
29(1):187-191.
PMID: 32328775
Background: Anti-estrogen therapy is an effective intervention for preventing reoccurrence of hormone receptor-positive breast cancer in women. However, the side effects of anti-estrogen therapy, including urogenital symptoms, have been reported...
9.
Segar J, Reed D, Stopeck A, Livingston R, Chalasani P
Oncologist
. 2019 Aug;
24(12):1512-e1267.
PMID: 31383812
Lessons Learned: The combination of irinotecan and etoposide showed modest efficacy in terms of response rate in the refractory setting for patients with metastatic breast cancer.The studied dose and schedule...
10.
Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, et al.
J Med Econ
. 2019 Aug;
23(1):37-47.
PMID: 31364885
Bone complications (also known as skeletal-related events [SREs]) pose significant health and financial burdens on patients with bone metastases. Denosumab demonstrated superiority over zoledronic acid in delaying the time to...